TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2648816

Group type: EXPERIMENTAL
Intervention: Electrocautery for 2 s (fixed duration cautery)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cautery until visible necrosis of the polyp base (variable duration cautery)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Visible necrosis achieved
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: No visible necrosis
Number of subjects: 35
Study: 29569536

Group type: EXPERIMENTAL
Intervention: Iodised salt intervention
Number of subjects: 1835
Study: 28796990

Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (GMA) with the Adacolumn as remission induction therapy
Number of subjects: 77
Study: 25924545

Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Number of subjects: 28

Group type: COMPARATOR
Intervention: Double Flap Approach (DFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Double Flap Approach (DFA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA) and Double Flap Approach (DFA)
Number of subjects: 28
Study: 23470303

Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation (1000 mg daily for 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 12
Study: 21712276

Group type: EXPERIMENTAL
Intervention: Endocardial radiofrequency (RF) catheter ablation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Endocardial RF catheter ablation
Number of subjects: 43
Study: 18573712

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1553
Study: 14622079

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) with significant other
Number of subjects: 132

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 132
Study: 10606851

Group type: EXPERIMENTAL
Intervention: 5% sodium nitrite co‐applied with 5% salicylic acid under occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical cream with 5% salicylic acid, omitting sodium nitrite
Number of subjects: 0
Study: 8682016

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation and secondary prevention programme lasting 3 years after acute myocardial infarction
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study: 2228838

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g iv
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g iv
Number of subjects: 12
Study: 121165

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (daily at least 1.1010 granulocytes per square meter from the last day of treatment until the 12th day of aplasia)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no prophylactic granulocyte transfusions, eligible for transfusions as clinically indicated)
Number of subjects: 50
Study: 31076461

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study: 28234436

Group type: EXPERIMENTAL
Intervention: Immediate discontinuation of prior antipsychotics at baseline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gradual discontinuation of prior antipsychotics by reducing 25% each week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Gradual)
Number of subjects: 33
Study: 25636135

Group type: EXPERIMENTAL
Intervention: Sauna bathing for 8 weeks
Number of subjects: 37
Study: 24174681

Group type: EXPERIMENTAL
Intervention: Theta-tACS during motor imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-tACS at rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21846904

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Aerobic Training + Resistance Training (AT/RT)
Number of subjects: 196
Study: 19957796

Group type: EXPERIMENTAL
Intervention: beta‐NGF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TrKA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: beta‐NGF and TrKA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: beta‐NGF mRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TrKA mRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P75(NGFR) mRNA
Number of subjects: 0
Study: 17426704

Group type: EXPERIMENTAL
Intervention: 5-FU/levamisole
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 5-FU/folinic acid
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: p53-/BAX high
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: BAX protein expression
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: MSI+ tumors
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: BAX or Bcl-2
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: MSI
Number of subjects: 188
Study: 15821379

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Butorphanol 0.04 mg/kg
Number of subjects: 40
Study: 11508586

Group type: EXPERIMENTAL
Intervention: Polymyalgia rheumatica (PMR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (PMR and RA)
Number of subjects: 28
Study: 9778225

Group type: EXPERIMENTAL
Intervention: Intravenous pulse administration of cyclophosphamide (0.75 gm/m2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide treatment (2 mg/kg body weight)
Number of subjects: 47
Study: 8170727

Group type: EXPERIMENTAL
Intervention: Accelerated schedule (0, 1, 2 months)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Routine schedule (0, 1, 6 months)
Number of subjects: 299
Study: 29871978

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Prior stroke/systemic embolism
Number of subjects: 18201
Study: 27484113

Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound (HIFU) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Whole lesion ablation (comparison for treatment time)
Number of subjects: 40
Study: 24964869

Group type: EXPERIMENTAL
Intervention: Individually tailored worksite‐based intelligent physical exercise training (IPET)
Number of subjects: 400
Study: 22785061

Group type: EXPERIMENTAL
Intervention: Tecnis toric intraocular lens (IOL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acrysof IQ toric IOL
Number of subjects: 40
Study: 20201089

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (Feraheme injection) administered as two 510 mg IV injections, separated by 3-8 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron (Ferro-Sequels) administered at a dose of 100 mg twice daily for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 0
Study: 19367170

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg orally)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 mg orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16721698

Group type: EXPERIMENTAL
Intervention: Hydrocortisone pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metyrapone pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metyrapone with PVCs
Number of subjects: 10
Study: 15702627

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11227291

Group type: EXPERIMENTAL
Intervention: Certoparin (18 mg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dalteparin (30 mg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Enoxaparin (24 mg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: All LMWHs
Number of subjects: 188
Study: 9266100

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ovarian ablation
Number of subjects: 39
Study: 8390529

Group type: EXPERIMENTAL
Intervention: Enalapril pretreatment (5 mg/day for 5 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Noradrenaline (0.075 micrograms/kg per min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of Enalapril and Noradrenaline
Number of subjects: 9
Study: 2894971

Group type: EXPERIMENTAL
Intervention: Felodipine (initial dose 2.5mg bid, titrated to 5, 10, 20mg bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prazosin (initial dose 0.5mg bid, titrated to 1, 2, 4mg bid)
Number of subjects: 100
Study: 31440954

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with obesity before surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with obesity after OAGB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with obesity
Number of subjects: 50
Study: 30352054

Group type: EXPERIMENTAL
Intervention: GSK3532795 (60 mg, 120 mg, or 180 mg QD) + TDF/FTC (300/200 mg QD)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Efavirenz (EFV) (600 mg QD) + TDF/FTC (300/200 mg QD)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: GSK3532795
Number of subjects: 206

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 206
Study: 27554946

Group type: EXPERIMENTAL
Intervention: Shock delivery in asystolic patients
Number of subjects: 9902

Group type: EXPERIMENTAL
Intervention: Shock delivery in PEA patients
Number of subjects: 9902
Study: 24482093

Group type: EXPERIMENTAL
Intervention: Thin and Popular
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thin and Average Popularity
Number of subjects: 66

Group type: COMPARATOR
Intervention: Heavy and Average Popularity
Number of subjects: 66
Study: 22963595

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM‐I)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy (cCBT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 63
Study: 20526762

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 18674992

Group type: EXPERIMENTAL
Intervention: Home-based motor imagery gait training (15 minutes, 3 days a week for 6 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Home-based motor imagery gait training
Number of subjects: 17
Study: 16168145

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not offered screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group offered screening
Number of subjects: 0
Study: 12608543

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS) applied to abdomen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS) applied to buttock and hip
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro Oxybutynin skin absorption
Number of subjects: 0
Study: 10509765

Group type: EXPERIMENTAL
Intervention: High-CHO diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-MUFA diet
Number of subjects: 30
Study: 8619355

Group type: EXPERIMENTAL
Intervention: Iobitridol (300 mg I/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iohexol (300 mg I/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Iobitridol and Iohexol)
Number of subjects: 80
Study: 1768163

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg weekly for six weeks (Group 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg weekly for three weeks (Group 1A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pamidronate 45 mg every three months for one year (Group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pamidronate (both groups)
Number of subjects: 15
Study: 6755247

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study: 31200736

Group type: EXPERIMENTAL
Intervention: Shi-style lumbar manipulation (SLM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mechanical lumbar traction
Number of subjects: 60
Study: 28433560

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study: 26152000

Group type: EXPERIMENTAL
Intervention: Time-limited hydrotubation combined with clomiphene citrate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 80
Study: 23567441

Group type: EXPERIMENTAL
Intervention: venlafaxine XR (up to 300 mg/day) for 12 weeks
Number of subjects: 277
Study: 20868450

Group type: EXPERIMENTAL
Intervention: lipoprotein components (LDL-C, HDL-C, apoB, apoA-1, TC/HDL-C, apoB/apoA-1)
Number of subjects: 9247
Study: 19299803

Group type: EXPERIMENTAL
Intervention: Continuous perineural femoral analgesia
Number of subjects: 217

Group type: COMPARATOR
Intervention: Multimodal analgesia
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo perineural femoral infusion
Number of subjects: 217
Study: 17519647

Group type: EXPERIMENTAL
Intervention: D-cycloserine (250 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (250 mg)
Number of subjects: 24
Study: 15292480

Group type: EXPERIMENTAL
Intervention: C&E (caffeine 70 mg/dose and ephedra 24 mg/dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C&E
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11506984

Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects (age 72 ± 3 years)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy young subjects (age 24 ± 1 year)
Number of subjects: 20
Study: 9414375

Group type: EXPERIMENTAL
Intervention: Keyboard and mouse with a three-dimensional arm support
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trackpoint device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Keyboard and mouse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Keyboard alone
Number of subjects: 20
Study: 7901473

Group type: COMPARATOR
Intervention: Corticosteroids (40 mg prednisolone daily, tapered and stopped after 12 weeks)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Elemental diet (with dietary advice on healthy eating)
Number of subjects: 136
Study: 3629220

Group type: EXPERIMENTAL
Intervention: Intramuscular gold therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral penicillamine therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: General practitioner monitoring
Number of subjects: 100
Study: 31056541

Group type: EXPERIMENTAL
Intervention: Family-based intervention (physiotherapeutic and familial component)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional early intervention
Number of subjects: 42
Study: 25993585

Group type: COMPARATOR
Intervention: Standard CCU alarm settings
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Altered CCU alarm settings
Number of subjects: 22
Study: 23406207

Group type: EXPERIMENTAL
Intervention: Baseline survey assessing genetic knowledge and attitudes toward genetic testing
Number of subjects: 300
Study: 21159326

Group type: EXPERIMENTAL
Intervention: ePREP intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 0
Study: 18621547

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) training for 7 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Voluntary isometric (VOL) training for 7 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 25
Study: 16972100

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 15148202

Group type: EXPERIMENTAL
Intervention: AC IOL
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PC IOL
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both AC IOL and PC IOL
Number of subjects: 110
Study: 12594647

Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis for PCP
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 146
Study: 9846777

Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 7851516

Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movements against an elastic load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isometric conditions
Number of subjects: 0
Study: 2571354

Group type: EXPERIMENTAL
Intervention: Prescription information leaflets (PILs) for penicillins, diuretics, and benzodiazepines
Number of subjects: 252

Group type: COMPARATOR
Intervention: No leaflets distributed (Control)
Number of subjects: 252
Study: 1056849

Group type: EXPERIMENTAL
Intervention: Toothpaste with active ingredients (allantoin, pyridyl carbinol, alpha‐tocopherol, potassium aluminum sulfate, tartaric acid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control toothpaste without additives
Number of subjects: 60
Study: 30394943

Group type: EXPERIMENTAL
Intervention: Questionnaire recall
Number of subjects: 741
Study: 28982175

Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC)
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: Dedicated service outlets (DSO)
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: IPC + DSO
Number of subjects: 5639

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5639
Study: 25532865

Group type: EXPERIMENTAL
Intervention: delta-9-THC (10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22841641

Group type: EXPERIMENTAL
Intervention: Recruitment of independent pharmacies
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Recruitment of chain pharmacies
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pharmacist enrollment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pharmacy technician enrollment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Median contacts per pharmacy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Duration from initial contact to consent
Number of subjects: 64
Study: 22403963

Group type: EXPERIMENTAL
Intervention: Perioperative music intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 19172289

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 18590259

Group type: EXPERIMENTAL
Intervention: DP-a (hydrofluoric acid treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IC-t (tribochemical silica coating)
Number of subjects: 18

Group type: COMPARATOR
Intervention: DP-s (sandblasting treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: DP-t (tribochemical silica coating)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IC-s (sandblasting treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IC-a (hydrofluoric acid treatment)
Number of subjects: 18
Study: 15294013

Group type: EXPERIMENTAL
Intervention: FP/salmeterol 100/50 microg twice daily via Diskus inhaler
Number of subjects: 447

Group type: COMPARATOR
Intervention: FP + montelukast 100 microg twice daily via Diskus inhaler plus oral montelukast 10mg once daily
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: FP/salmeterol
Number of subjects: 447

Group type: COMPARATOR
Intervention: FP + montelukast
Number of subjects: 447
Study: 11878725

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Multimodal analgesia with i.v. patient controlled analgesia (i.v. PCA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) and i.v. PCA
Number of subjects: 54
Study: 9628276

Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60 microg pramlintide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 90 microg pramlintide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7523181

Group type: EXPERIMENTAL
Intervention: rhG‐CSF administration
Number of subjects: 4

Group type: COMPARATOR
Intervention: H 7 (10 mumol/l) or H 8 (20 mumol/l) co-incubation
Number of subjects: 4
Study: 2536255

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1111913

Group type: EXPERIMENTAL
Intervention: BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: DTIC 300 mg/m2/day x 6 given every 30 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: DTIC 100 mg/m2/8 hours x 18 given every 30 days
Number of subjects: 120
Study: 31291969

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (hRT) with protons (57.0/3.0 Gy RBE)
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (hRT) with photons (57.0/3.0 Gy)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Normofractionated radiotherapy (nRT) with photons (70.0/2.0 Gy)
Number of subjects: 897